<DOC>
	<DOC>NCT00497198</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy of MCI-196 in patients with Type 2 Diabetes based on the changes in blood glucose-related parameters and safety after 12 weeks administration in double-blind, placebo-controlled manner. And in addition, the changes in lipid-related parameters are examined.</brief_summary>
	<brief_title>Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Bile Acids and Salts</mesh_term>
	<criteria>Patients whose fasting blood glucose levels during the observation period are between 130mg/dL and 200mg/dL. Patients whose HbA1c is 7.0% or above during the observation period. Patients with serious cardiac, hepatic or renal complications. Patients with serious diabetic complications. Patients with complete biliary obstruction or ileus. Pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>anion-exchange resin</keyword>
</DOC>